-Bloomberg
Novo Nordisk’s Higher Dose Oral Semaglutide Shows Superior Reductions In Sugar Levels, Body Weight
Novo Nordisk A/S (NYSE:NVO) announced headline results from the PIONEER PLUS phase 3b trial of oral semaglutide 25 mg and 50…
Related Posts
Apple’s Break With Goldman Sachs, iCloud Security Concerns, Vision Pro Cost Cuts And More: This Week In Appleverse
Another bustling weekend has passed in the world of technology, with Apple Inc. (NASDAQ:AAPL) making headlines. The tech giant made…
Roth Capital Initiates Coverage On Phibro Animal Health with Buy Rating, Announces Price Target of $18
Roth Capital analyst Brian Wright initiates coverage on Phibro Animal Health (NASDAQ:PAHC) with a Buy rating and announces Price Target of $18.
Apple’s India Story Turns Fresh Page: Tata Group Chosen To Make iPhone 15 Series
The story was first published on the Benzinga India Portal.